Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia

Table 3

Frequency of comorbidities or prior splenectomy per group.

	DFO	DFX	DFO + DFP	𝑃 value
Myocardial dysfunction	33.3%	6.7%	15.4%	0.0058
Hepatic dysfunction	38.1%	6.7%	2.6%	<0.0001
Thyroid disease	28.6%	58.7%	53.8	0.0499
Hypogonadism	14.3%	10.7%	10.3%	NS
Splenectomy	71.4%	38.7%	48.7%	0.0319
Allergies	14.3%	9.3%	2.6%	0.0487

DFO: deferoxamine; DFX: deferasirox; DFP: deferiprone; NS: not significant. 𝑃 values < 0.05 indicate statistical differences among the three groups.